BCL2 and cancer: The tumor control mediated by Bcl2-/- de-iniDCs was further enhanced by subsequent PD-1 blockade, as shown for both TC1 (Fig. 4A-D) and MCA205 cancers (Fig. S8C-F), but was lost upon depletion of T cells by means of neutralizing antibodies specific to CD4 and CD8 (Fig. 4G,H, Fig. S8G), as well as in nude mice lacking mature T cells due to the Foxn1nu/nu mutation (Fig. S8H).